You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Core labs remain closed or at reduced operations due to the COVID-19 pandemic, leading to concerns about the state of their businesses when they can reopen.
The team will present the results to the US Food and Drug Administration as part of a 510(k) application in order to commercialize the technology with Biofluidica.
With several SBIR grants from the NIH, the firm is also using its Liquid Scan platform to identify neonatal trophoblast cells in maternal blood samples.
Research groups and companies are developing and applying tools to enrich for and capture CTCs to diagnose tumors early and monitor patients during treatment.
Researchers used thousands of conserved sequences for more than 100 songbird species to reconstruct their diversification and historical expansion route.
Genomic, transcriptomic, and phylogenetic data suggest a group of microscopic parasites within the cnidarian lineage has undergone extensive body plan streamlining.
The partners will collaborate on pediatric oncology research, with a goal of earning an NCI designation of Comprehensive Cancer Center.
The NCRR funding will fund clinical and translational science centers and partnerships centered at five universities.
NHGRI's rare diseases program will partner with The University of Kansas and the Leukemia and Lymphoma Society to speed up therapeutic development.
According to unaudited, pro forma data, Panomics would have added $10.7 million to Affy's total revenues for the nine months ended Sept. 30, 2008, and $11 million to the company's top line in fiscal year 2007.
Nature News reports on the US National Science Foundation's investigations of undisclosed foreign ties among researchers it funds.
Researchers have developed a set of 10 principles to guide how a list of all species on earth should be put together, the Guardian reports.
Wired reports on a new firm developing a gene writing approach for therapeutic genome changes.
In Nature this week: a method called cis-X combines whole-genome and transcriptome sequencing data to identify regulatory noncoding variants, and more.